CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
This CE/CME/CEU-accredited supplement is jointly provided by
Release date: May 10, 2017
Expiration date: May 10, 2018
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Estimated time to complete activity: 1.0 hour
The ASCO Post
94 North Woodhull Road
Huntington, NY 11743
This activity is supported by an educational grant from Lilly. For further information regarding Lilly grant funding visit www.lillygrantoffice.com.
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center, Dana-Farber Cancer Institute, Boston
Sara A. Hurvitz, MD, Director of the Breast Oncology, Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center
Activity Rationale and Purpose
Inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) have emerged as a novel class of targeted agents in the treatment of patients with cancer. As these agents become more widely used in clinical practice for multiple tumor types beyond breast cancer, health-care professionals will need to become familiar with the rationale behind this type of therapy and how best to use these agents to make appropriate treatment decisions. This supplement to The ASCO Post will provide oncologists and other oncology professionals with evidence-based updates on the biology, unique toxicity profile, and clinical potential of CDK4/6 inhibitors.
The activity’s target audience will consist of oncology researchers, medical oncologists, and other health-care professionals with an interest in researching and/or using CDK4/6 inhibitors in treating patients with cancer.
After completing this educational activity, participants should be able to:
1. Explain the rationale for considering CDK4/6 as a therapeutic target in breast cancer and the mechanism of action of CDK4/6 inhibitors.
2. Indicate other tumor types in which this type of therapy may have potential.
3. Anticipate and manage toxicities that may occur with the use of CDK 4/6 inhibitors.
4. Describe the goals and challenges for the future broader introduction and clinical use of CDK4/6 inhibitors for cancer therapy, including awareness of and referral to ongoing clinical trials.
Statement of Credit—Participants who successfully complete this activity (including the submission of the posttest and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.
Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-17-039-H01-P. This program is designated for up to 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credit.
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Geoffrey I. Shapiro, MD, PhD, has reported receiving a commercial research grant from Pfizer and is a consultant/advisory board member for Eli Lilly, EMD Serono, G1 Therapeutics, and Vertex Pharmaceuticals.
Sara A. Hurvitz, MD, has received research support from Amgen, Bayer, Boehringer Ingelheim, Genentech, GSK, Pfizer, Roche, Biomarin, Merrimack, PUMA, Dignitana, Medivation, Lilly, Novartis, OBI Pharma; and travel expenses from Lilly, Novartis, and OBI Pharma.
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER
John Bayliss, VP, Business Development at the Annenberg Center for Health Sciences at Eisenhower, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
James O. Armitage, MD, University of Nebraska Medical Center, has no potential conflicts of interest to disclose.
Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has no potential conflicts of interest to disclose.
Harborside Press and Harborside Medical Education staff have no potential conflicts of interest to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population. The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
Select the Start button to complete the learning assessment and evaluation.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Attendance